SIGLECs (conserved)

Home
Targets
Other protein targets
Sialic acid binding Ig like lectins (SIGLECS)
SIGLECs (conserved)

Unless otherwise stated all data on this page refer to the human proteins. Gene information is provided for human (Hs), mouse (Mm) and rat (Rn).

Overview

Show »« Hide

This subfamily of 4 SIGLECs share conserved sequence homology. SIGLEC15 from this group has been implicated in myeloid cell-mediated modulation in cancer making it a novel therapeutic target to enhance antitumour immunity (cancer immunotherapy) [1,3-4,6-7].

Targets

SIGLEC2 (CD22) Show summary »« Hide summary More detailed page go icon to follow link

Target Id	2786
Nomenclature	CD22
Common abbreviation	SIGLEC2
Previous and unofficial names	B-lymphocyte cell adhesion molecule \| sialic acid binding Ig-like lectin 2 \| SIGLEC-2
Genes	CD22 (Hs)
Ensembl ID	ENSG00000012124 (Hs)
UniProtKB AC	P20273 (Hs)

SIGLEC15 (sialic acid binding Ig like lectin 15) Show summary »« Hide summary

Target Id	3265
Nomenclature	sialic acid binding Ig like lectin 15
Common abbreviation	SIGLEC15
Previous and unofficial names	CD33 antigen-like 3 \| CD33L3
Genes	SIGLEC15 (Hs), Siglec15 (Mm), Siglec15 (Rn)
Ensembl ID	ENSG00000197046 (Hs), ENSMUSG00000091055 (Mm), ENSRNOG00000033588 (Rn)
UniProtKB AC	Q6ZMC9 (Hs), A7E1W8 (Mm), D3ZL05 (Rn)
Comment	An anti-SIGLEC15 monoclonal antibody has been used experimentally to establish the therapeutic anti-cancer potential of targeting this receptor on tumour-associated macrophages [2,5].

References

Show »« Hide

1. Gao HY, Liu GJ, Qiu YR. (2024) Siglec-15 regulates cell proliferation, migration and invasion in bladder cancer. Asian J Surg, [Epub ahead of print]. [PMID:38169162]

2. He F, Wang N, Li J, He L, Yang Z, Lu J, Xiong G, Yu C, Wang S. (2021) High affinity monoclonal antibody targeting Siglec-15 for cancer immunotherapy. J Clin Transl Res, 7 (6): 739-749. [PMID:34988324]

3. Huang Z, Guo Y, Li B, Shen M, Yi Y, Li L, Zhao X, Yang L. (2024) Siglec-15 on macrophages suppress the immune microenvironment in patients with PD-L1 negative non-metastasis lung adenocarcinoma. Cancer Gene Ther, 31 (3): 427-438. [PMID:38072971]

4. Moreira RS, da Silva MM, de Melo Vasconcelos CF, da Silva TD, Cordeiro GG, Mattos-Jr LAR, da Rocha Pitta MG, de Melo Rêgo MJB, Pereira MC. (2023) Siglec 15 as a biomarker or a druggable molecule for non-small cell lung cancer. J Cancer Res Clin Oncol, 149 (19): 17651-17661. [PMID:37843557]

5. Wang J, Sun J, Liu LN, Flies DB, Nie X, Toki M, Zhang J, Song C, Zarr M, Zhou X et al.. (2019) Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy. Nat Med, 25 (4): 656-666. [PMID:30833750]

6. Wang J, Xu L, Ding Q, Li X, Wang K, Xu S, Liu B. (2023) Siglec15 is a prognostic indicator and a potential tumor-related macrophage regulator that is involved in the suppressive immunomicroenvironment in gliomas. Front Immunol, 14: 1065062. [PMID:37325664]

7. Wu Q, Wei X, Chen F, Huang M, Zhang S, Zhu L, Zhou L, Yang C, Song Y. (2023) Aptamer-Assisted Blockade of the Immune Suppressor Sialic Acid-Binding Immunoglobulin-Like Lectin-15 for Cancer Immunotherapy. Angew Chem Int Ed Engl, 62 (52): e202312609. [PMID:37955317]

How to cite this family page

Database page citation:

SIGLECs (conserved). Accessed on 27/04/2024. IUPHAR/BPS Guide to PHARMACOLOGY, http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=1094.

Concise Guide to PHARMACOLOGY citation:

Alexander SPH, Kelly E, Mathie AA, Peters JA, Veale EL, Armstrong JF, Buneman OP, Faccenda E, Harding SD, Spedding M, Cidlowski JA, Fabbro D, Davenport AP, Striessnig J, Davies JA et al. (2023) The Concise Guide to PHARMACOLOGY 2023/24: Introduction and Other Protein Targets. Br J Pharmacol. 180 Suppl 2:S1-22.